KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Cash from Investing Activities (2018 - 2025)

Vir Biotechnology's Cash from Investing Activities history spans 8 years, with the latest figure at $86.7 million for Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 38.43% year-over-year to $86.7 million; the TTM value through Dec 2025 reached $310.4 million, down 37.85%, while the annual FY2025 figure was $310.4 million, 37.85% down from the prior year.
  • Cash from Investing Activities for Q4 2025 was $86.7 million at Vir Biotechnology, up from $40.4 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $230.3 million in Q2 2023 and bottomed at -$662.6 million in Q3 2022.
  • The 5-year median for Cash from Investing Activities is $65.2 million (2021), against an average of -$18.0 million.
  • The largest annual shift saw Cash from Investing Activities surged 612.09% in 2021 before it plummeted 997.12% in 2022.
  • A 5-year view of Cash from Investing Activities shows it stood at -$377.6 million in 2021, then surged by 59.44% to -$153.1 million in 2022, then skyrocketed by 31.56% to -$104.8 million in 2023, then surged by 234.28% to $140.7 million in 2024, then tumbled by 38.43% to $86.7 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Cash from Investing Activities are $86.7 million (Q4 2025), $40.4 million (Q3 2025), and $56.5 million (Q2 2025).